Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue Up 46% in Q4
Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.
Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
Novo Nordisk is looking into acquiring or developing a long-acting GLP-1 drug that could compete with Pfizer’s monthly obesity shot.
Pfizer beat Novo in the ferocious battle to acquire …
GLP-1 obesity drugs can complicate life for people with disordered eating
Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders.
More GLP-1 Drug Lawsuits; Military’s Rising Obesity Rates; Male Birth Control Soon?
(MedPage Today) — More lawsuits are alleging that patients are not being sufficiently warned of certain severe injuries associated with GLP-1 receptor agonists. (USA Today)
Meanwhile, the U.K.’s Medicines and Healthcare Products Regulatory Agency…
Rethinking weight loss in the Ozempic era: Researchers urge a more holistic view
In the world of obesity research, the arrival of GLP-1 drugs like Ozempic feels seismic. At a recent conference, Martin Binks, a leader in obesity research, found himself marveling with a colleague: “Can you believe we finally reached this moment, that we lived long enough to see this?”
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA PF’3944 Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
NEW YORK–(BUSINESS WIRE) February 03, 2026 — Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1…
STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition
Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.
China NMPA approves Sciwind’s GLP-1 injection for diabetes
Sciwind Biosciences Co. Ltd. said Jan. 30 it won Chinese approval for self-developed glucagon-like peptide-1 (GLP-1) receptor agonist, ecnoglutide (Xianyida), to treat adults with type 2 diabetes.
Pfizer’s Metsera GLP-1 hits mark for once-monthly dosing
Nearly three months after winning a contentious bid to buy obesity drugmaker Metsera Inc. for $10 billion, Pfizer Inc. reported its first statistically significant top-line data of the acquired lead, ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, showing a mean placebo-adjusted weight loss of up to 12.3% at 28 weeks, as well as competitive tolerability.
GLP-1 drugs tied to lower-calorie, lower-sugar food purchases
Researchers at Steno Diabetes Center Copenhagen reported that starting a GLP-1 receptor agonist (GLP-1RA) coincided with slightly healthier supermarket purchases. Grocery purchases from GLP-1RA users in Denmark contained modestly fewer calories and sugars and slightly more protein per 100 g of food after treatment began than before.